It’s all systems go for Moon Surgical with a new FDA green light for its Maestro robotic laparoscopy platform.

Digital business cards. Gilead’s virtual reality ride. Soccer’s Champions League final. A motorcycle brigade. This year’s American Society of Clinical Oncology (ASCO) conference in Chicago marked a return to its pre-pandemic heyday.

Dexcom announced that its G7 diabetes sensor can now link directly to a user’s Apple Watch, allowing them to track their glucose readings in real-time even if their iPhone isn’t nearby.

Vir Biotechnology’s hepatitis D combination therapy has shown early efficacy in results from a phase 2 trial, suggesting the drug cocktail may pose a threat to Gilead Sciences’ stuttering attempt to capture the market.

The FDA’s “Operation Warp Speed” equivalent for rare disease will include programs from Denali Therapeutics, Neurogene, Larimar Therapeutics and Grace Science, the companies announced June 3 in separate press releases.

Though immunotherapies have made strong inroads in the fight against cancer, knowing which drugs will work the best in which patients—and with the first dose—has remained a challenge.

Hypertrophic cardiomyopathy, or HCM, is a common but potentially lethal heart disease. While researchers have tried for decades to understand the contribution of the many genes linked to the condition, challenges and inefficiencies around growing heart muscle cells with only specific mutations—and no others that could cloud results—has hampered progress.

Annexon’s monoclonal antibody ANX005 reduced disability in patients with the rare autoimmune disorder Guillain-Barré syndrome (GBS), meeting the main goal of a phase 3 trial.

Alkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect despite being administered less frequently.

BridgeBio Pharma has bounced back from the withdrawal of infigratinib in oncology, linking the molecule to a BioMarin-beating height increase in children with a growth disorder in a midphase clinical trial.